These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17487370)

  • 1. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
    Szepeshazi K; Schally AV; Halmos G
    Int J Oncol; 2007 Jun; 30(6):1485-92. PubMed ID: 17487370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
    Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
    Cancer; 1999 Jun; 85(12):2608-15. PubMed ID: 10375109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
    Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
    Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
    Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM
    Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A; Schally AV
    Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
    Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
    Breast Cancer Res Treat; 2000 Feb; 59(3):255-62. PubMed ID: 10832595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
    Szepeshazi K; Schally AV; Halmos G; Armatis P; Hebert F; Sun B; Feil A; Kiaris H; Nagy A
    Cancer Res; 2002 Feb; 62(3):781-8. PubMed ID: 11830533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
    Szepeshazi K; Schally AV; Nagy A; Halmos G; Groot K
    Anticancer Drugs; 1997 Nov; 8(10):974-87. PubMed ID: 9436641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
    Szepeshazi K; Schally AV; Nagy A; Wagner BW; Bajo AM; Halmos G
    Cancer; 2003 Oct; 98(7):1401-10. PubMed ID: 14508826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
    Miyazaki M; Nagy A; Schally AV; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
    J Natl Cancer Inst; 1997 Dec; 89(23):1803-9. PubMed ID: 9392622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Westphal G; Halmos G; Engel JB
    Cancer Res; 2005 Jul; 65(13):5857-63. PubMed ID: 15994963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
    Keller G; Schally AV; Nagy A; Halmos G; Baker B; Engel JB
    Cancer; 2005 Nov; 104(10):2266-74. PubMed ID: 16211544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
    Krebs LJ; Wang X; Pudavar HE; Bergey EJ; Schally AV; Nagy A; Prasad PN; Liebow C
    Cancer Res; 2000 Aug; 60(15):4194-9. PubMed ID: 10945629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Eur J Cancer; 2005 Sep; 41(14):2196-202. PubMed ID: 16182122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.